Table 1 Characteristics of included studies
Study | Register number | Country | Patients | Age (years) | Male (%) | Phase | ECOG status | Chemotherapy drug | Pembrolizumab arm | Study design | |
|---|---|---|---|---|---|---|---|---|---|---|---|
2020 | Charles [12] | NCT03066778 | America | Arm A (n = 228) | 64 (24-81) | 66.7 | ES-SCLC | 0/1 | Platinum plus etoposide | Pembrolizumab 200 mg, Q3W, iv for 35 cycles | Randomized controlled trial |
Arm B (n = 225) | 65 (37-83) | 63.1 | 0/1 | - | |||||||
2017 | Ott [13] | NCT02054806 | America | 24 | 60.5 (41-80) | 58.3 | ES-SCLC | 0/1 | Platinum plus etoposide | Pembrolizumab 10 mg/kg, Q2W, iv for 24 months | Noncomparative open-label study |
2018 | Shirish [14] | NCT02359019 | America | 45 | 66 (50-86) | 56 | ES-SCLC | 0/1 | Platinum plus etoposide | Pembrolizumab 200 mg, Q3W, iv for 24 months | Noncomparative open-label study |
2019 | Kim [15] | NCT02551432 | Korea | 26 | 68.5 (54–78) | 88.5 | ES-SCLC | 0/1 | Platinum plus etoposide and paclitaxel | Pembrolizumab 175 mg/m2, Q3W, iv for 5 cycles | Noncomparative open-label study |
2019 | Welsh [16] | NCT02402920 | America | 38 | 65 (37–79) | 61 | ES-SCLC | - | Platinum plus etoposide | Pembrolizumab 200 mg, Q3W, iv for 16 cycles | Noncomparative open-label study |
2020 | Welsh [17] | NCT02402920 | America | 40 | 64 (41−79) | 40 | LS-SCLC | - | Platinum plus etoposide | Pembrolizumab 200 mg, Q3W, iv for up to 16 cycles | Noncomparative open-label study |